Literature DB >> 2469713

Comparative effect of recombinant IL-1, -2, -3, -4, and -6, IFN-gamma, granulocyte-macrophage-colony-stimulating factor, tumor necrosis factor-alpha, and histamine-releasing factors on the secretion of histamine from basophils.

R Alam1, J B Welter, P A Forsythe, M A Lett-Brown, J A Grant.   

Abstract

Most cytokines possess multiple biologic activities. This study was undertaken to investigate the effect of rIL-1 beta, -2, -3, -4 and -6, IFN-gamma, TNF-alpha, and granulocyte-macrophage (GM)-CSF on basophils from 16 donors and the amount of histamine released was compared with that by partially purified mononuclear cell-derived histamine-releasing factor (HRF) and anti-IgE. We found that only IL-3 and GM-CSF at relatively high doses (50 to 500 ng/ml) released small amounts of histamine (3 to 14%) from two allergic donors. In contrast, both HRF and anti-IgE released significant amounts of histamine from all donors. Other cytokines did not release any measurable quantity of histamine. Simultaneous addition of several cytokines to the basophils also failed to release histamine. IL-3, GM-CSF, and IL-1 can also release histamine at lower concentrations (less than 5 ng/ml) when incubated with basophils in the presence of D2O. Basophils from 6 out of 13 allergic donors released histamine in response to IL-3, whereas three donors responded to IL-1 beta and two responded to GM-CSF. The results of this study demonstrated that although IL-3 and GM-CSF release small amounts of histamine only from a select group of allergic patients, mononuclear cell-derived HRF is more potent in their action and release histamine from normals as well as allergic patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469713

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Increased plasma tumour necrosis factor-alpha concentration in atopic dermatitis.

Authors:  S Sumimoto; M Kawai; Y Kasajima; T Hamamoto
Journal:  Arch Dis Child       Date:  1992-03       Impact factor: 3.791

2.  Regulation of human basophil activation; the role of Na+ and Ca2+ in IL-3-induced potentiation of IgE-mediated histamine release from human basophils.

Authors:  F Beauvais; K Echasserieau; C Burtin; J Benveniste
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

Review 3.  Evaluation of TNF as antiviral, antibacterial and antiparasitic agent.

Authors:  G A Rook; J Taverne; J H Playfair
Journal:  Biotherapy       Date:  1991

4.  Isolation and characterization of trypsin-like and chymotrypsin-like proteinases from human cholesteatoma.

Authors:  K Hochstrasser; G J Albrecht; W Gebhard; G Rasp; E Kastenbauer
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

5.  Effects of interleukins on connective tissue type mast cells co-cultured with fibroblasts.

Authors:  F Levi-Schaffer; V Segal; M Shalit
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

6.  Interactions of IFN-gamma with IL-3 and IL-4 in the regulation of serotonin and arachidonate release from mouse peritoneal mast cells.

Authors:  M R Holliday; E M Banks; R J Dearman; I Kimber; J W Coleman
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

7.  Characterization of histamine-releasing activity: role of cytokines and IgE heterogeneity.

Authors:  T N Liao; K H Hsieh
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

Review 8.  Chronic urticaria.

Authors:  A Leznoff
Journal:  Can Fam Physician       Date:  1998-10       Impact factor: 3.275

9.  Pharmacological investigations with different protein kinase C inhibitors on IgE-dependent and IgE-independent activation of human basophils.

Authors:  U Amon; E von Stebut; H H Wolff
Journal:  Agents Actions       Date:  1993-05

10.  Monocyte chemotactic and activating factor is a potent histamine-releasing factor for basophils.

Authors:  R Alam; M A Lett-Brown; P A Forsythe; D J Anderson-Walters; C Kenamore; C Kormos; J A Grant
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.